HOUSE COMMITTEE ON
AUDIT & HUMAN SERVICES BUDGET REFORM
April 08, 2003 Hearing Room 50
3:15 PM Tapes 88
- 89
MEMBERS PRESENT: Rep. Ben Westlund, Chair
Rep. Steve March, Vice-Chair
Rep. Jeff Kruse
Rep. Jeff Merkley
Rep. Alan Bates
MEMBERS EXCUSED: Rep. Randy Miller
Rep. Susan Morgan, Vice-Chair
GUEST MEMBERS: Rep.
Mitch Greenlick
Rep. Laurie Monnes Anderson
Rep. Carolyn Tomei
STAFF PRESENT: Rick
Berkobien, Committee Administrator
Kelly Fuller, Committee Assistant
ISSUES HEARD: Informational
Meeting - Invited Testimony Only
Fully Capitated Health Plan's
Management of Prescription Drugs
Patricia Gibford, CEO, Central
Oregon Independent Health Services
Chris Kirk, MD, Mid Valley
Independent Physicians Association
These minutes are in
compliance with Senate and House Rules.
Only text enclosed in quotation marks reports a speaker’s exact
words. For complete contents,
please refer to the tapes.
|
TAPE/# |
Speaker |
Comments |
|
TAPE 88, A |
||
|
003 |
Chair Westlund |
Opens the informational meeting and asks staff if
they have any announcements. |
|
INFORMATIONAL
MEETING |
||
|
010 |
Berkobien |
Gives an explanation of the information presented by
staff at the dais. (EXHIBIT A). |
|
016 |
Chair Westlund |
Introduces the witnesses and calls them to the dais. |
|
025 |
Pat Gibford |
Introduces herself presents her testimony (EXHIBIT B) and begins her
presentation. |
|
093 |
Rep. Monnes Anderson |
Asks for a definition of what the 30-69 means. |
|
096 |
Gibford |
Gives an explanation that it is the average per
member per month for our Oregon Health Plan membership and elaborates. |
|
103 |
Rep. Greenlick |
Asks if that means the dispensing fee is less than
two dollars per prescription. |
|
106 |
Gibford |
Responds yes and Continues presentation. |
|
112 |
Chair Westlund |
Asks if this if for Feb. 2003 or as of Feb. 2003 and
asks if 98 percent of your drugs we formulary drugs then 1.95 percent were
non formulary drugs, so you went through your prior authorization process. |
|
132 |
Gibford |
Responds yes and continues. |
|
138 |
Rep. Tomei |
Asks what class of drugs would those be. |
|
143 |
Gibford |
Comments that there are not mental health drugs in
here and explains and continues. |
|
172 |
Berkobien |
Asks if there is an appeal process that you have to
go through. |
|
177 |
Gibford |
Responds yes and usually it is the physicians and
explains. |
|
212 |
Rep. Kruse |
Asks for the definition of PAR. |
|
215 |
Gibford |
Gives explanation that PAR is Prior Authorization
Required |
|
220 |
Rep. Kruse |
Comments for clarification that you have to get
prior authorization for formulary drugs and some other drugs on the
list. Asks if it is a different
process. |
|
223 |
Gibford |
Responds no, and explains. |
|
228 |
Rep. Kruse |
Asks why is there then a generic drug on page two (EXHIBIT B) requiring prior
authorization. |
|
243 |
Chris Kirk |
Introduces himself as the Medical Director for
Mid-Valley Individual Physicians Association and responds to the question on
page two of (EXHIBIT B). |
|
261 |
Rep. Bates |
Asks what was the process to make a choice on what
was on and what was off by the pre-authorization required list. |
|
308 |
Gibford |
Comments that the decision process was multi-faceted
and elaborates. |
|
316 |
Rep. Bates |
He noticed that you use a PBM (Pharmacy Benefit
Manager) and yet you say a PBM doesn’t fill all the needs you have because
they don’t have the relations between you and your physicians. |
|
320 |
Gibford |
Responds to some degree that is correct and
elaborates. |
|
329 |
Rep. Bates |
Asks if someone wanted to approach you would they go
through you or the PBM. |
|
314 |
Gibford |
Responds that they would go through the PBM. Continues presentation. |
|
331 |
Berkobien |
Asks how your formulary compares with the drug class
list that the state is using. |
|
342 |
Gibford |
Responds to the drug class list and end her
presentation. |
|
366 |
Kirk |
Begins his presentation. (EXHIBIT C) |
|
TAPE 89, A |
||
|
110 |
Rep. Tomei |
Curious about the remarks that some people choose
not to go for rebates, could you explain. |
|
113 |
Kirk |
There are people in the industry that feel that the
rebate strategy is un-ethical. |
|
108 |
Rep. Tomei |
Asks why they think it might be un-ethical. |
|
111 |
Kirk |
Responds and elaborates. |
|
120 |
Rep. Merkley |
Asks if this is just an overall strategy to reduce
drug prices. |
|
127 |
Kirk |
Responds yes. |
|
129 |
Chair Westlund |
Makes comments about pharmaceutical rebates. |
|
135 |
Rep. Merkley |
Does the rebate come as a check or as a discount on
the bill. |
|
140 |
Kirk |
Responds that they will give you an estimated rebate
and explains. |
|
160 |
Berkobien |
Comments about a national hearing that involved some
of the larger PBM’s, getting rebates themselves and sharing with their
consumers but not wanting to say how much they were getting themselves, are
your PBM’s open with the type of medications that they might promote to you
and how do you deal with that. |
|
170 |
Kirk |
Responds if their rebates are based on a PBM you
need to watch them and elaborates. |
|
177 |
Gibford |
Adds to the comments. |
|
182 |
Rep. Tomei |
Asks the more drugs you use the higher the rebate. |
|
186 |
Kirk |
Responds yes. |
|
188 |
Gibford |
Also responds with an analogy. |
|
192 |
Rep. Bates |
Asks if they ever audit their PBM. |
|
194 |
Gibford |
Responds no, they have not. |
|
196 |
Kirk |
Responds that they have not found a company to
audit. |
|
212 |
Chair Westlund |
Asks why don’t they use AEL to audit their PBM’s. |
|
215 |
Kirk |
Responds that they do on an ad-hoc basis and
explains. |
|
242 |
Rep. Kruse |
Asks if AEL checks to make sure that you are getting
the best rebates possible. |
|
246 |
Kirk |
Comments when advanced PCS gives us a recommendation
we ask AEL for their advise. |
|
249 |
Rep. Kruse |
Asks if they save them money. |
|
253 |
Kirk |
Responds yes and elaborates. |
|
|
Rep. Greenlick |
Asks what the difference in price is. |
|
|
Kirk |
Responds approximately 1 dollar per pill. |
|
291 |
Rep. Merkley |
When you said that they settled for 5 million are
you talking about a rebates of which you would have gotten a share or that’s
a payment that is completely independent from the rebates. |
|
293 |
Kirk |
Comments no, they would not have seen a dime of that
and elaborates. |
|
304 |
Rep. Merkley |
Comments that you mentioned the clause you use and
is it an unusual provision and will they allow you to do that again. |
|
313 |
Kirk |
Responds that he does not know and continues. |
|
381 |
Berkobien |
Asks if they use pill splitting. |
|
386 |
Kirk |
Comments that they do not have a formal policy on
that but have made it an educational piece. |
|
394 |
Berkobien |
Can you ball park the costs in pill splitting if you
did do a mandatory policy. |
|
402 |
Kirk |
Makes comments about pill splitting if it was
mandatory. |
|
TAPE 88, B |
||
|
007 |
Vice Chair March |
Comments that there are some drugs that do qualify
for pill splitting. |
|
011 |
Kirk |
Comments that, that is exactly right and explains
that they have material on that fact and continues presentation. (EXHIBIT
C) |
|
065 |
Rep. Greenlick |
Asks if he did anything in his education and
community in unnecessary prescriptions of antibiotics and etc. |
|
071 |
Kirk |
Responds that they have not found an opportunity
there yet and comments about academic detailing. |
|
076 |
Rep. Greenlick |
Comments that it has not proven to be do effective
when you evaluate it. |
|
079 |
Kirk |
States that it made an impact and continues. |
|
082 |
Rep. Greenlick |
One way is to look at the prescription utilization
rates, have you done that. |
|
088 |
Kirk |
Responds whether or not they have looked at those
rates and give examples. |
|
102 |
Gibford |
Comments that we have done some sorts of those
things and explains. |
|
120 |
Rep. Tomei |
Asks how they handled the incident discussed. |
|
122 |
Kirk |
Responds that they have not done that yet and
explains. |
|
137 |
Rep. Tomei |
With something not on the formulary do the customers
have to pay for that themselves. |
|
149 |
Berkobien |
Can you speak generally about how the OHP formulary cost
compare to some of the commercial products. |
|
151 |
Gibford |
Responds that it is difficult to compare and makes
general comments about why. |
|
164 |
Rep. Tomei |
Would it be safe to assume that most of the
population is older.. |
|
169 |
Gibford |
Comments no, that most on Medicaid are in their 20’s. |
|
172 |
Vice Chair March |
Reiterates the question to make more clear and asks
what would cause the difference in the OHP population and the commercial. |
|
177 |
Gibford |
Responds with an educated guess. |
|
206 |
Kirk |
In summary says in trying to control the pharmacy
costs and having worked for 5 states at a time, the local relationships in
Salem make a difference and it really does work. |
|
222 |
Vice Chair March |
Calls meeting to a close and adjourns 4:30 pm |
EXHIBIT
SUMMARY
A
– Informational, prepared material, staff 2 pp
B
– Informational, prepared testimony, Pat Gibford, 38 pp
C
– Informational, prepared testimony, Chris Kirk, 19 pp